<DOC>
	<DOCNO>NCT02311439</DOCNO>
	<brief_summary>This prospective cohort , phase II , trial study induction chemotherapy combination , FOLFIRINOX regimen , consist oxaliplatin , irinotecan , leucovorin fluorouracil ( 5-FU ) , 4 cycle , follow consolidation concurrent radiotherapy capecitabine non-progressed case , treat patient locally advanced cancer pancreas .</brief_summary>
	<brief_title>Induction Chemotherapy , FOLFIRINOX Followed With Concurrent Capecitabine Radiation Therapy Inoperable Locally Advanced Cancer Pancreas</brief_title>
	<detailed_description>Design &amp; Methodology : 1 . Nature study : It ( prospective cohort study ) . 2 . Study subject : *Target Population : Patients , fulfil inclusion criterion research , select Assiut clinical oncology department Assiut University Hospitals . - Sample size : 20 patient . - Characteristics subject : - Inclusion criterion : Disease characteristic : - Histological radiological confirmation locally advance cancer pancreas - Inoperable disease - Disease must able encompass within radical radiotherapy treatment volume - Not metastatic Patient characteristic : - ECOG performance status 0 1 - Life expectancy &gt; 3 month . - Glomerular filtration rate ≥ 60 mL/min . - WBC &gt; 3,000/mm³ . - Absolute neutrophil count &gt; 1,500/mm³ . - Hemoglobin &gt; 10.0 g/dL . - Platelet count &gt; 100,000/mm³ . - Alkaline phosphatase ≤ 1.5 time upper limit normal ( ULN ) - Gamma-glutamyl-transferase &lt; 1.5 time ULN . - Transaminases ≤ 1.5 time ULN . - Bilirubin ≤ 1.5 time ULN . - No medically unstable condition ( e.g. , unstable diabetes , uncontrolled arterial hypertension , infection , hypercalcemia , ischemic heart disease ) - Not pregnant nursing . - No previous current malignant disease likely interfere protocol treatment comparison - No prior chemotherapy radiotherapy . 3 . Patients &amp; Methods : Patients randomize one treatment arm . Induction 4 time chemotherapy , FOLFIRINOX regimen , consist Oxaliplatin dose 85 mg/m2 day 1 , administer 2-hour intravenous infusion , addition , 30 minute , Irinotecan dose 180 mg/m2 day 1 give 90-minute intravenous infusion . immediately follow Leucovorin dose 200 mg/m2 , give 2- hour intravenous infusion , day 1 day 2 This treatment follow fluorouracil ( 5-FU ) dose 400 mg/m2 , administer intravenous bolus day 1 day 2 , follow continuous intravenous infusion 600 /m2 20- hour period day 1 day 2 . Treatment administer every 2 week . G-CSF administrate accord need . In non-progressed case , induction chemotherapy follow consolidation radiotherapy concurrent capecitabine 625 mg/m2 BID . Radiotherapy : A fractionate dose 50.4Gy /28 fraction/15 MeV photon energy generate Dual-energetic Linear Accelerator . - Gross Target Volume ( GTV ) : visible tumor lymph node . - Clinical Target Volume ( CTV ) : [ tumor/ affect lymph node + 1-2 cm ] + regional lymphatics Lymphatics : corpus : upper low pancreaticoduodenal , superior inferior pancreatic , celiac Head : corpus lymphatics + porta hepatis lymphatics Tail : corpus lymphatics ( except pancreaticoduodenal LN ) + splenic hilum LN - PTV : CTV + 1-1.5 cm - All patient undergo complete classical evaluation time presentation enrol separate sheet patient . This include detailed history estimation age onset , duration disease , . - Detailed physical examination carry Treatment evaluation . Laboratory examination include - complete blood count ( CBC ) , - liver function test ( LFT ) - Renal function test ( RFT ) , - Serum electrolytes presentation cycle chemotherapy . Radiographic examination include - Abdominal Multi Detector Computed Tomography ( MDCT Abdomen ) - Chest X-ray Before start treatment , 2 week end phase 1 treatment 4 week end phase 2 treatment every 3 month 18 month . ● Bone scan do complain bone pain ; elevate serum alkaline phosphatase transaminase level - Quality life assess baseline , monthly 6 month , follow-up visit . After completion study treatment , patient follow periodically . Response Assessment : carry , use ( RECIST ) Response Evaluation Criteria In Solid Tumors , Version 1.1 Chemotherapy Toxicity Assessment : carry , use ( CTCAE ) Common Terminology Criteria Adverse Events , Version 4.0 4 . Data analysis : Data analyse use computer program , Statistical Package Social Science ( SPSS V.16 ) . Expected outcome : The outcome study compare statistically previous local international trail . Ethical consideration : 1 . Risk-benefit assessment : There acceptable risk may affect patient research study regard acceptable side effect Gemcitabine , Oxaliplatin radiotherapy . 2 . Confidentiality : Any data take patient either history , examination investigation confidential . 3 . Research statement : All patient subject study inform procedure research . 4 . Informed consent : The study procedure discuss patient consent take . 5 . Other ethical concern : The research conduct scientifically qualify trained personnel .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Disease characteristic : Histological radiological confirmation locally advance cancer pancreas Inoperable disease Disease must able encompass within radical radiotherapy treatment volume Not metastatic Patient characteristic : ECOG performance status 0 1 Life expectancy &gt; 3 month . Glomerular filtration rate ≥ 60 mL/min . WBC &gt; 3,000/mm³ . Absolute neutrophil count &gt; 1,500/mm³ . Hemoglobin &gt; 10.0 g/dL . Platelet count &gt; 100,000/mm³ . Alkaline phosphatase ≤ 1.5 time upper limit normal ( ULN ) Gammaglutamyltransferase &lt; 1.5 time ULN . Transaminases ≤ 1.5 time ULN . Bilirubin ≤ 1.5 time ULN . No medically unstable condition ( e.g. , unstable diabetes , uncontrolled arterial hypertension , infection , hypercalcemia , ischemic heart disease ) Not pregnant nursing . No previous current malignant disease likely interfere protocol treatment comparison No prior chemotherapy radiotherapy . ECOG performance status &gt; 2 Life expectancy &lt; 3 month . Glomerular filtration rate &lt; 30 mL/min . Absolute neutrophil count &lt; 1,500/mm³ . Alkaline phosphatase &gt; 1.5 time upper limit normal ( ULN ) Gammaglutamyltransferase &gt; 1.5 time ULN . Transaminases &gt; 1.5 time ULN . Bilirubin &gt; 1.5 time ULN . medically unstable condition ( e.g. , unstable diabetes , uncontrolled arterial hypertension , infection , hypercalcemia , ischemic heart disease ) pregnant nursing . prior chemotherapy radiotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Locally advanced pancreatic cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>